← Back to Search

Androgen Replacement Therapy

Natesto for Low Testosterone

Phase 4
Recruiting
Led By Kevin Campbell, MD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to 26 weeks
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial
No Placebo-Only Group

Summary

This trial will study if Natesto can help men on testosterone therapy to regain fertility while avoiding hypogonadal symptoms.

Who is the study for?
Men aged 18-64 with low testosterone (<350 ng/dL) and reduced sperm count, who have stopped testosterone treatments for at least 4 weeks. They should be in good health overall, seeking to father a child, and have either primary or secondary hypogonadism diagnosed.
What is being tested?
The trial is testing NatestoTM to see if it can relieve symptoms of low testosterone while helping men recover their sperm production for the purpose of conceiving.
What are the potential side effects?
Possible side effects include allergic reactions to ingredients in NatestoTM, issues related to nasal administration such as irritation or discomfort, and typical risks associated with testosterone therapy like mood changes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 26 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 26 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in total motile sperm count

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: NatestoTMExperimental Treatment1 Intervention
Participants in this group will receive Natesto for a 26 consecutive weeks treatment course

Find a Location

Who is running the clinical trial?

Acerus PharmaceuticalUNKNOWN
University of FloridaLead Sponsor
1,395 Previous Clinical Trials
767,264 Total Patients Enrolled
Kevin Campbell, MDPrincipal InvestigatorUniversity of Florida

Media Library

NatestoTM (Androgen Replacement Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05381831 — Phase 4
Testicular Hypogonadism Research Study Groups: NatestoTM
Testicular Hypogonadism Clinical Trial 2023: NatestoTM Highlights & Side Effects. Trial Name: NCT05381831 — Phase 4
NatestoTM (Androgen Replacement Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05381831 — Phase 4
~1 spots leftby Dec 2024